U.S. Markets open in 7 hrs 29 mins

Albany Molecular Research, Inc. (AYM.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
17.9180.000 (0.000%)
As of 9:08AM CEST. Market open.
Full screen
Previous Close17.918
Open0.000
Bid0.000 x 26300
Ask0.000 x 25300
Day's Range0.000 - 0.000
52 Week Range
Volume20
Avg. Volume1
Market Cap776.89M
BetaN/A
PE Ratio (TTM)-12.63
EPS (TTM)-1.42
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR
    PR Newswire20 days ago

    AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR

    ALBANY, N.Y. , Aug. 31, 2017 /PRNewswire/ -- Albany Molecular Research, Inc. (NASDAQ: AMRI), a global contract research, development and manufacturing organization working with the life sciences industry ...

  • American City Business Journalslast month

    AMRI shareholders approve sale of company

    Shareholders of Albany Molecular Research Inc. on Friday approved the sale of the pharmaceutical research company to affiliates of private-equity firms based in Chicago and Washington, D.C. The vote comes a little more than two months after the drug developer's board unanimously approved the sale of the AMRI to affiliates of The Carlyle Group and GTCR LLC . The private-equity firms have agreed to pay $21.75 per share, an equivalent of more than $900 million to purchase the Albany, New York, region's third-largest public company.

  • PR Newswire3 months ago

    AMRI Announces Early Termination of HSR Waiting Period for The Carlyle Group and GTCR's Proposed Acquisition of AMRI

    ALBANY, N.Y., June 29, 2017 /PRNewswire/ -- Albany Molecular Research, Inc. (AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with the proposed acquisition of AMRI by affiliates of The Carlyle Group ("Carlyle") and GTCR LLC ("GTCR"). As previously announced, on June 5, 2017, AMRI entered into a definitive agreement to be acquired by Carlyle and GTCR for $21.75 per share in cash. It is anticipated that the special meeting of AMRI's stockholders to vote on the transaction will be held in the third quarter of 2017, and, if the transaction is approved, the merger would be expected to close shortly thereafter.